NicOx : Garufi ... e la Rivoluzione Pharma
- Creatore Discussione Yesod
- Data di Inizio
- Stato
DickSIM
Prima o poi....ci becco!
sulla creatura nitrica! 
DickSIM
Prima o poi....ci becco!
e dopo le news lo svago a base di pompe!!!!!!!!!!!!!!!!!miscredenti tremate le pompate del trio medusa son tornate!!!!!!!!!!!!!!!!! che si aprano le danze
/
presto il trio sarà portato in trionfo dai suoi estimatori.........
ugotega
Forumer storico
http://www.ebdgroup.com/bes/program.htm
c'è per caso qualche volontario disposto ad imbucarsi al buffet organizzato dalla camera di commercio di milano domani alle 19 al castello sforzesco?...
c'è per caso qualche volontario disposto ad imbucarsi al buffet organizzato dalla camera di commercio di milano domani alle 19 al castello sforzesco?...
doctor NO
NO nel DNA
Le Celebrex est en difficulté. Auj. à 10:16
Le Celebrex est en difficulté.
Le contexte est intéressant pour les négociations de partenariat du Naproxcinod.
Le CA du Celebrex repose sur l’antériorité des prescriptions (les changements d’habitudes) ou le marketing.
Le marketing du Naproxcinod pourra s’attaquer à tous les marchés y compris à celui du Celebrex (la plupart du temps non prescrit). Le marketing des candidats partenaires ne manquera pas de réévaluer ce marché.
Le doute sur la validité des études du Celebrex sera exploité par les concurrents. La difficulté est que le marketing actuel est celui du marketing des génériques et donc beaucoup moins puissant que celui de Pfizer.
Pour le moment rien n’indique que les autorités de santé vont mettre en cause le Celebrex voire le retirer du marché. C’est la seule situation où le Celebrex ne serait plus prescrit.
Le CA du Celebrex diminuera sans doute (voire ne fera que stagner en fonction de la puissance marketing de Pfizer). Les publications Danoises sur le risque cardio-vasculaire des AINS vont sensibiliser l’opinion médicale. L’arrivée du Naproxcinod devrait opportunément offrir une alternance des prescriptions des médecins.
Nicox et les candidats partenaires en ont bien conscience.
Le Naproxcinod continu de surfer sur la déferlante de l’échec des COX2.
Le Celebrex est en difficulté.
Le contexte est intéressant pour les négociations de partenariat du Naproxcinod.
Le CA du Celebrex repose sur l’antériorité des prescriptions (les changements d’habitudes) ou le marketing.
Le marketing du Naproxcinod pourra s’attaquer à tous les marchés y compris à celui du Celebrex (la plupart du temps non prescrit). Le marketing des candidats partenaires ne manquera pas de réévaluer ce marché.
Le doute sur la validité des études du Celebrex sera exploité par les concurrents. La difficulté est que le marketing actuel est celui du marketing des génériques et donc beaucoup moins puissant que celui de Pfizer.
Pour le moment rien n’indique que les autorités de santé vont mettre en cause le Celebrex voire le retirer du marché. C’est la seule situation où le Celebrex ne serait plus prescrit.
Le CA du Celebrex diminuera sans doute (voire ne fera que stagner en fonction de la puissance marketing de Pfizer). Les publications Danoises sur le risque cardio-vasculaire des AINS vont sensibiliser l’opinion médicale. L’arrivée du Naproxcinod devrait opportunément offrir une alternance des prescriptions des médecins.
Nicox et les candidats partenaires en ont bien conscience.
Le Naproxcinod continu de surfer sur la déferlante de l’échec des COX2.
DickSIM
Prima o poi....ci becco!
Generex Biotechnology Announces Successful Phase III Study Data for Generex Oral-lyn(tm) - (MobiWire)
WORCESTER, Mass., -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, yesterday announced positive results following the review of the Phase III data for the Company's flagship product, Generex Oral-lyn, a proprietary oral insulin spray product designed to replace prandial injections of insulin.
Generex, together with the Company's independent third party statistical and data monitoring consultants, will continue to monitor the ongoing pivotal Phase III Generex Oral-lyn study according to protocol and national/international ICH-GCPs. To date, more than 300 subjects have been enrolled in the study (with 60 subjects having achieved the requisite six-month treatment milestone) and the product's non-inferiority to injectable meal-time (prandial) insulin appears to be maintained. If the current positive trend is maintained, then a large reduction of required enrollment will suffice for formal verification of the non-inferiority hypothesis.
The current data also demonstrates that no significant Generex Oral-lyn drug-related "Adverse Events" or "Serious Adverse Events" have been reported, which also supports the current initiatives of the study.
"The current data and trends represent a critical milestone for the Company," said Anna Gluskin, Generex's President and Chief Executive Officer. "These results are consistent with the results of our previous studies. This will allow us greater flexibility in our strategies for filing submissions with regulatory authorities in major global markets and other jurisdictions where applications are already in progress."
The Company believes that Generex Oral-lyn will offer a safe, simple, fast, effective and pain-free alternative to prandial insulin injections which will improve patient compliance with therapeutic regimes thereby delaying the progress of diabetes and the onset of its myriad complications.
WORCESTER, Mass., -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, yesterday announced positive results following the review of the Phase III data for the Company's flagship product, Generex Oral-lyn, a proprietary oral insulin spray product designed to replace prandial injections of insulin.
Generex, together with the Company's independent third party statistical and data monitoring consultants, will continue to monitor the ongoing pivotal Phase III Generex Oral-lyn study according to protocol and national/international ICH-GCPs. To date, more than 300 subjects have been enrolled in the study (with 60 subjects having achieved the requisite six-month treatment milestone) and the product's non-inferiority to injectable meal-time (prandial) insulin appears to be maintained. If the current positive trend is maintained, then a large reduction of required enrollment will suffice for formal verification of the non-inferiority hypothesis.
The current data also demonstrates that no significant Generex Oral-lyn drug-related "Adverse Events" or "Serious Adverse Events" have been reported, which also supports the current initiatives of the study.
"The current data and trends represent a critical milestone for the Company," said Anna Gluskin, Generex's President and Chief Executive Officer. "These results are consistent with the results of our previous studies. This will allow us greater flexibility in our strategies for filing submissions with regulatory authorities in major global markets and other jurisdictions where applications are already in progress."
The Company believes that Generex Oral-lyn will offer a safe, simple, fast, effective and pain-free alternative to prandial insulin injections which will improve patient compliance with therapeutic regimes thereby delaying the progress of diabetes and the onset of its myriad complications.
- Stato